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Background: Although most deaths among patients with type 2 diabetes (T2D) are attributable to cardiovascular
disease, modifiable cardiovascular risk factors appear to be inadequately treated in medical practice. The aim of this study
was to describe hypertension, dyslipidemia and medical treatment of these conditions in a large population-based
sample.
Methods: The present analysis was based on the DIAB-CORE project, in which data from five regional population-based
studies and one nationwide German study were pooled. All studies were conducted between 1997 and 2006. We
assessed the frequencies of risk factors and co-morbidities, especially hypertension and dyslipidemia, in participants with
and without T2D. The odds of no or insufficient treatment and the odds of pharmacotherapy were computed using
multivariable logistic regression models. Types of medication regimens were described.
Results: The pooled data set comprised individual data of 15, 071 participants aged 45–74 years, including 1287 (8.5%)
participants with T2D. Subjects with T2D were significantly more likely to have untreated or insufficiently treated
hypertension, i.e. blood pressure of >= 140/90 mmHg (OR=1.43, 95% CI 1.26-1.61) and dyslipidemia i.e. a total
cholesterol/HDL-cholesterol ratio>= 5 (OR=1.80, 95% CI 1.59-2.04) than participants without T2D. Untreated or
insufficiently treated blood pressure was observed in 48.9% of participants without T2D and in 63.6% of participants with
T2D. In this latter group, 28.0% did not receive anti-hypertensive medication and 72.0% were insufficiently treated. In
non-T2D participants, 28.8% had untreated or insufficiently treated dyslipidemia. Of all participants with T2D 42.5% had
currently elevated lipids, 80.3% of these were untreated and 19.7% were insufficiently treated.
Conclusions: Blood pressure and lipid management fall short especially in persons with T2D across Germany. The
importance of sufficient risk factor control besides blood glucose monitoring in diabetes care needs to be emphasized in
order to prevent cardiovascular sequelae and premature death.
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Atherosclerosis accounts for most deaths in people with
type 2 diabetes (T2D) and the age adjusted relative risk of
coronary artery disease and peripheral arterial disease has
been reported to be threefold higher than in the general
population [1-3]. In a population-based study conducted
by Haffner et al. 1998 [4], the 7-year incidence of first myo-
cardial infarction or death was 18.8% in T2D patients com-
pared to 3.5% in non-T2D persons. Cerebrovascular
disease is also more common in subjects with T2D due to
limited cerebrovascular arterial circulation and cerebral
hemodynamic and vascular derangements [5]. As a precur-
sor of frank T2D, insulin resistance has been shown to in-
crease the risk of cardiovascular events in non-diabetic
patients without history of myocardial infarction or stroke
[6] and the risk of new cardiovascular events in non-
diabetic patients with manifest arterial disease [7]. The
findings indicate that insulin resistance per se and
independently of other components of the metabolic
syndrome, including inflammation, has an influence on
cardiovascular risk.
Hypertension and dyslipidemia are often associated with
insulin resistance, frequent in T2D and enhance the risk of
macrovascular complications like coronary artery disease
and stroke as well as microvascular sequelae like retinop-
athy and nephropathy [8].
Thus, subjects with T2D particularly profit from lifestyle
modifications and medication therapy aiming at a normo-
tensive blood pressure and low lipid concentrations in the
blood [1].
Nevertheless, several studies in Germany and other coun-
tries have shown that patients in primary care [9-11] and
particularly patients with T2D are not adequately treated
with antihypertensive and lipid lowering medications. In
general, about 50% of patients do not reach a blood pres-
sure of < -140/90 mmHg and about the same proportion of
patients have dyslipidemia, depending on the definition
used [12-18].Table 1 Studies included in the pooled DIAB-CORE sample (45
Study Region St
SHIPa North-east Germany (West Pomerania) 19
DHSb West Germany (Dortmund) 20
CARLAc East Germany (Halle) 20
NHRd West Germany (Bochum, Essen, Mühlheim an der Ruhr) 20
KORAe South Germany (Augsburg region) 19
GNHIES98f Nationwide 19
Total Germany 19
aSHIP: Study of Health in Pomerania; bDHS: Dortmund Health Study; cCARLA: Cardio
eKORA (Survey S4): Cooperative Health Research in the Region of Augsburg; fGNHIEObjectives
While patient-related data from primary care and patients-
registries are available demonstrating an under-treatment of
T2D patients in clinical practice, results from population-
based studies are scarce. Such data, however, are important
to generalize knowledge on the treatment status of specific
populations and to identify regional differences in the qua-
lity of health care. Moreover, studies using clinical practice
data probably underestimate frequencies since well-treated
patients are more likely to be recruited.
In the current analysis, we used pooled data from the
DIAB-CORE data set to assess the frequencies of risk
factors associated with cardiovascular disease (CVD), co-
morbidities, medication intake, adequate and insufficient
treatment in participants with and without T2D from
Germany. Our pre-specified hypothesis based on current
literature was that blood pressure and lipid levels are not
sufficiently controlled, particularly in patients with T2D.
Methods
Study design and setting
The DIAB-CORE Consortium has been launched in order
to establish a joint pool of population-based data on persons
with and without diabetes. Six studies covering regions in
Germany were combined (from north to south): the Study of
Health in Pomerania (SHIP, Greifswald), the Dortmund
Health Study (DHS, Dortmund), the Cardiovascular Disease,
Living and Ageing (CARLA, Halle-Wittenberg) Study, the
Heinz Nixdorf-Risk Factors, Evaluation of Coronary Calcifi-
cation, and Lifestyle (HNR Recall, Bochum, Essen, Mülheim
a. d. Ruhr) Study, the Cooperative Health Research in the
Region of Augsburg (KORA, Augsburg) Study, and the na-
tionwide German National Health Interview and Examin-
ation Survey 1998 (GNHIES98, Germany), see Table 1.
All studies were conducted between 1997 and 2006 and
used similar instruments, questionnaires and medical mea-
surements to collect data. Detailed descriptions of study
designs, samples and procedures are available elsewhere–74 years), north to south
udy period N (%) Age (years)
mean (SD)
Women (%) T2D (%)
97–2001 2247 (14.9) 59.0 (8.3) 1128 (50.2) 251 (11.2)
03-2004 883 (5.9) 60.1 (8.5) 447 (50.6) 87 (9.9)
02–2006 1382 (9.2) 60.2 (7.9) 651 (47.1) 174 (12.6)
00-2003 4734 (31.4) 59.6 (7.8) 2379 (50.3) 350 (7.4)
99–2001 2442 (16.2) 58.9 (8.4) 1227 (50.3) 146 (6.0)
97–1999 3383 (22.5) 58.0 (8.0) 1749 (51.7) 279 (8.3)
97–2006 15071 59.1 (8.1) 7581 (50.3) 1287 (8.5)
vascular Disease, Living and Ageing in Halle; dHNR: Heinz Nixdorf-Recall;
S98: German National Health Interview and Examination Survey 1998.
Rückert et al. Cardiovascular Diabetology 2012, 11:50 Page 3 of 14
http://www.cardiab.com/content/11/1/50[19-25]. Ethical approval and written informed consent was
obtained for each study.
Variables
Age
Only participants aged 45 to 74 years were included in the
pooled data set, representing the common intersection of
all studies.
School education
A binary variable was created contrasting individuals with
high and middle educational graduation (higher educational
entrance qualification, advanced technical college entrance
qualification, general certificate of secondary education or
polytechnic grammar school) versus low educational gradu-
ation (no school certificate or junior high school only).
Income
Participants were asked to choose their appropriate income
class. The midpoints of these classes were used to define
the variable household net income separately for each re-
gional study. The lowest income group was defined as less
than 60% of the median income in the individual study and
was compared to the other groups.
Smoking
Two categories (current vs. ex- and never smoker) were
defined to differentiate risk types. A current smoker smoked
at least one cigarette per day. An ex-smoker had quit smok-
ing at least one year ago, otherwise he or she was regarded
as a current smoker.
Body mass index
Body mass index was calculated as weight in kilograms
divided by height in square meters (unit kg/m2).
Physical activity
In all studies physical activity was assessed by self-report
only. A threshold of <= 1 h per week was determined as
physical inactivity. Assessment of physical activity included
all kinds of exercise training but did not comprise low level
exercise such as stepping stairs or walking, as this type of
exercise was not assessed in all studies.
T2D
T2D was defined based on self-report of physician's diagno-
sis or self-reported intake of oral anti-diabetic agents, insulin
or a combination of both. Some studies lacked information
on diabetes type. Thus, in order to exclude participants who
probably had Type 1 diabetes, self-reported age at diagnosis
of diabetes was used, and only those patients with an age at
diagnosis of >30 years were included in the T2D group.Hypertension
Hypertension was defined using the mean of the second and
third blood pressure measurements (the first and second
measurements in DHS) conducted at the study centres with
systolic blood pressure>=140 and/or diastolic blood
pressure>=90 mmHg, or intake of anti-hypertensive medi-
cation in participants with physician’s diagnosis of hyperten-
sion (“awareness”). Participants with hypertension were
categorized into one of the following four subgroups: (1)
aware (with physician’ diagnosis) and controlled treated to
target levels of <140/90 mmHg, (2) aware and treated, but
not reaching target blood pressure values of<140/90 mmHg,
i.e. insufficiently treated, (3) aware, but not treated, (4) un-
aware of hypertension. Thus, “awareness” of hypertension
applied to participants in categories 1, 2 and 3, “treatment”
applied to those in categories 1 and 2 and “control” to those
in category 1[26].
Hypertension guidelines [27-31] launched after 2000, ad-
vocate treating blood pressure to <140/90 mmHg in per-
sons without diabetes and<130/80 mmHg in persons with
diabetes. The lower threshold for patients with diabetes or
persons at high risk for cardiovascular disease, respectively,
is relatively new and has been criticized by recent publica-
tions [32]. Due to intense medical treatment, subjects are
more likely to experience side effects, such as hypotension,
hypokalemia and worsening of renal function. German
guidelines also question the benefit of a lower blood pres-
sure goal because of inconsistent clinical evidence [33].
Thus, we chose a blood pressure of < 140/90 mmHg as a
goal in both participants with and without diabetes.
Dyslipidemia
Total cholesterol, high-density lipoprotein (HDL) cholesterol
and low-density lipoprotein (LDL) cholesterol levels were
measured from random blood samples. Dyslipidemia was
defined analogous to hypertension using information on
lipid-lowering medication intake, self-reported information
on physician's diagnoses and a total cholesterol to HDL
cholesterol ratio (TC/HDL) of >= 5 [34]. According to the
Adult Treatment Panel III 2001 of the US National Institutes
of Health [35], diagnosis of dyslipidemia should be based on
LDL cholesterol levels (> 100 mg/dl in high risk persons,
> 160 mg/dl in persons without additional CVD risk factors).
However, if the testing opportunity is non-fasting, only total
cholesterol and HDL cholesterol levels are usable. Kinosian
et al. [36] suggested that the ratio of total cholesterol to
HDL cholesterol has a better potential to discriminate
people at high risk of future cardiovascular disease than total
cholesterol or LDL cholesterol values respectively.
Burden of CVD
Self-reported data on myocardial infarction and stroke
(“Did you ever have a myocardial infarction/stroke, diag-
nosed by a physician?”) was assessed identically in all
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reference) and intermittent claudication was also collected,
although the questions were not identical across the stud-
ies. However, we tried to achieve the best possible
harmonization by using all available information. Prevalent
CVD was defined as presence of self-reported MI, stroke,
angina or claudication.
Anti-hypertensive medication
All study participants were asked to bring original packaging
of their medications used during the last seven days to the
examination. Unique pharmaceutical identifiers, names etc.
were recorded and ATC (Anatomical Therapeutic Chemical
Classification System) codes were assigned accordingly. The
variable “anti-hypertensive medication” included any pre-
scription of medication belonging to the ATC subgroups
C02 (antihypertensives), C03 (diuretics), C04 (peripheral
vasodilators), C07 (beta blocking agents), C08 (calcium
channel blockers) and C09 (agents reacting on the renin-
angiotensin system).
Lipid-lowering medication
Medications of the ATC subgroup C10 (lipid modifying
agents) were included in the variable “lipid-lowering
medication”.
Participants
Our pooled data set included 1287 participants with T2D
and 13784 participants without T2D aged 45 to 74 years
from major regions in Northeast, Middle, West- and
South-Germany. Two-stage cluster sampling or stratified
random sampling were used. In the nationwide survey
GNHIES98, 3% non-German but German speaking citizens
were included. KORA, SHIP, CARLA and HNR focused on
participants of German nationality, in DHS nationality was
not used as an inclusion criterion. Overall response ranged
between 56% and 69%.
Since physician's diagnosis of dyslipidemia had not been
assessed in DHS, the study was not included in analyses
using the combined variable of medication intake, laboratory
measurements and physician's diagnosis to classify partici-
pants with dyslipidemia. Because of missing values, partici-
pants had to be excluded from the hypertension sub-
analyses (n=358), and from the dyslipidemia sub-analyses
(n=1460) using these combined variables. Participants were
excluded from the logistic regressions on current hyperten-
sive measurements (n=26) and current dyslipidemia
(n=337), due to missing information on blood pressure or
lipid measurements. Participants (n=4612) with complete
variable information on the combined hypertension variable,
who had a positive physician’s diagnosis and used anti-
hypertensive medication were included to assess the frequen-
cies of medication classes.Statistical analyses
Men and women with diabetes and participants without dia-
betes were compared with respect to their lifestyle factors,
cardiovascular burden, clinical measurements and medica-
tions. For continuous variables means and standard devia-
tions (SD) were calculated, while categorical variables were
described as percentages. Differences between groups were
tested using t-tests and Wilcoxon tests (continuous vari-
ables) or chi-square tests and univariate logistic regression
models (categorical variables). Logistic regression models
were calculated to identify the effects of a basic set of vari-
ables that influence odds of hypertension, dyslipidemia and
medication intake, respectively.
A two-sided alpha level of 0.05 was chosen as criterion
for statistical significance. All analyses were carried out
using SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Participants
The pooled sample included 15071 participants (47.1-51.7%
women across studies) aged 45–74 years (Table 1). Overall
1287 (8.5%) participants had T2D (706 (54.9%) men and
581 (45.1%) women). The proportion of participants with
T2D according to the standardized definition in DIAB-
CORE ranged between 6.0% in KORA to 12.6% in CARLA.
The national survey study reported 8.3% respondents with
T2D. The mean age of all participants was 59.1 (SD=8.1).
The flow chart (Figure 1) indicates the numbers of partici-
pants within subgroups of interest.
Study characteristics
Participants with T2D were older than participants with-
out T2D (Table 2). Significantly more men than women
presented with T2D. On average, participants with T2D
had a BMI of 30.8 kg/m2, compared to 27.9 kg/m2 in
participants without diabetes. Participants with T2D
smoked less. However, they were also less physically ac-
tive, were characterized by lower income and lower edu-
cational status, particularly women. Subjects with T2D
had higher systolic and diastolic blood pressure than
non-T2D participants, 82.5% were classified as hyperten-
sive compared to 59.0% of participants without T2D.
They had more favourable total cholesterol- and LDL
cholesterol values but less favourable HDL cholesterol
values, and were more frequently diagnosed with dyslipi-
demia (54.8% vs. 35.7%).
Manifest cardiovascular diseases were generally about
twice to threefold as common among study participants
with T2D with 11.0% who had previously experienced
myocardial infarction compared to 4.1% in participants
without T2D (Table 2). 7.1% of subjects with T2D
reported a stroke versus 2.4% of participants without
T2D. Similar differences were observed for intermittent
claudication and angina pectoris.
Figure 1 Participant selection (flow chart).
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Of participants with T2D who had complete variable infor-
mation on medication intake and study measurements
(N=1270), 82.5% had hypertension compared to 59.0% in
non-T2D participants. Considering the four subgroups,
18.9% of all participants with T2D were controlled treated
(1) with mean blood pressure: 125/77 mmHg, 40.9% were
insufficiently treated (2) with mean blood pressure: 159/
91 mmHg, 6.7% were aware of the disease but not treated
(3) with mean blood pressure: 159/95 mmHg and 16.0%
were not aware (4) with mean blood pressure: 151/
91 mmHg. Anti-hypertensive medications were taken by
69.7% of subjects, by 59.8% of subjects with known hyper-
tension, i.e. 9.9% probably used these medications for a
different indication. On site measurements of >=140/90 mmHg, e.g. untreated or insufficiently treated hyperten-
sion was recorded in 63.6%. In comparison, the percentage
of participants without T2D with untreated or insufficiently
treated hypertension was 48.9% of 13443 subjects with
complete variable information (Table 3, Figure 2). Anti-
hypertensive medications were used by 34.5% of non-T2D
participants and by 28.7% with diagnosed hypertension.
Frequency and medical treatment of dyslipidemia
Of all T2D participants with complete data on intake of lipid
modifying medication, physician's diagnosis and laboratory
measurements (n=1161, without DHS), 54.8% were classi-
fied as having dyslipidaemia. The four subgroups displayed
the following frequencies: 12.3% were controlled treated (1)
with mean TC/HDL: 3.7, 7.2% were insufficiently treated (2)
Table 2 Study characteristics in DIAB-CORE, age range 45-74
Type 2 diabetes Non-type 2 diabetes
Men, n = 706 Women, n = 581 All, n = 1287 All, n = 13784
Age (years) 62.5 (7.2) 63.8 (7.1)* 63.1 (7.2) 58.7 (8.1)◯
Women (%) - - 45.1 50.8◯
BMI (kg/m2) 30.1 (4.8) 31.6 (5.7)* 30.8 (5.3) 27.9 (4.5)◯
BMI >= 30 (%) 41.8 58.1* 49.2 27.6◯
Smoking (%) 20.8 8.9* 15.5 21.3◯
Low physical activity (%) 73.2 71.6 72.5 58.0◯
Low income (%) 13.7 21.9* 17.3 12.5◯
Low education (%) 73.5 83.6* 78.1 63.6◯
Diabetes duration (years) 8.8 (7.7) 8.2 (7.2) 8.5 (7.5) -
Diabetes treatment (%)
Diet only or no treatment (%) 22.1 23.4 22.7 -
OAD only (%) 52.8 47.0 50.2 -
Insulin only (%) 15.5 18.8 17.0 -
OAD and Insulin (%) 9.7 10.8 10.2 -
Blood pressure (mmHg)
Systolic BP (mm Hg) 149.1 (22.1) 145.8 (21.8)* 147.6 (22.0) 138.5 (21.5)◯
Diastolic BP (mm Hg) 85.0 (11.4) 82.1 (10.9)* 83.7 (11.3) 84.5 (11.4)◯
⋄Hypertension (%) 80.7 84.8 82.5 59.0◯
current BP>= 140/90 (%) 67.0 59.6* 63.6 48.9◯
Cholesterol (mg/dl)
TC (mg/dl) 216.4 (48.0) 232.2 (48.8)* 223.5 (49.0) 236.2 (43.7)◯
LDL (mg/dl) 132.1 (37.8) 142.1 (41.5)* 136.6 (39.8) 149.5 (39.5)◯
HDL (mg/dl) 46.3 (14.0) 54.0 (16.6)* 49.8 (15.7) 58.4 (17.7)◯
⋄⋄Dyslipidemia (%) 56.7 52.5 54.8 35.7◯
current TC/HDL ratio >= 5 (%) 45.7 36.5* 41.6 28.8◯
Myocardial infarction (%) 13.7 7.7* 11.0 4.1◯
Stroke (%) 8.4 5.5* 7.1 2.4◯
Claudicatio intermittens (%) 13.3 10.6 12.1 3.8◯
Angina pectoris (%) 16.4 20.6* 18.3 9.3◯
History of CVD (%) 34.3 32.3* 33.4 15.5◯
Numbers are means (SD) or percentages and relate to the number of subjects available for analysis.
BMI: body mass index, OAD: oral anti-diabetic medication, TC: total cholesterol, LDL: low-density lipoprotein, HDL: high-density lipoprotein, CVD: cardiovascular
disease, BP: blood pressure.⋄BP>= 140/90 mmHg or using anti-hypertensive medication.⋄⋄TC/HDL >= 5 or using lipid-lowering medication.
*Test of the difference between T2D men and T2D women, p <0.05.
◯Test of the difference between all T2D subjects and all non-T2D subjects, p < 0.05.
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but not treated (3) with mean TC/HDL: 6.4 and 18.1% were
not aware (4) with mean TC/HDL: 6.1. Currently elevated
lipids (TC/HDL>=5), i.e. untreated or insufficiently treated
dyslipidemia was recorded in 42.5%. Lipid lowering medica-
tions were taken by 23.2% of participants (and by 19.6% with
known dyslipidemia, i.e. 3.6% probably used these medica-
tions for a different indication). In non-T2D study partici-
pants, 35.7% of 12450 with complete cholesterol, physicianand medication variables had dyslipidemia, 28.8% were un-
treated or insufficiently treated. Lipid lowering medications
were used by 10.7% of non-T2D participants (by 9.3x% with
diagnosed dyslipidemia) (Table 3, Figure 3).
Basic factors that influence treatment goals and the odds
of using medication
Fitting logistic regression models including all study parti-
cipants without missing values (N=15045), we found that
Table 3 Frequencies of hypertension, dyslipidemia, and adequacy of treatment in participants with and without T2D
Type 2 diabetes Non-type 2 diabetes
Men, n = 706 Women, n = 581 All, n = 1287 All, n = 13785
Complete cases hypertension n(cc) = 698 n(cc) = 572 n(cc) = 1270 n(cc) = 13443
No hypertension 135 (19.3) 87 (15.2) 222 (17.5) 5509 (41.0)◯
Hypertension 563 (80.7) 485 (84.8) 1048 (82.5) 7934 (59.0)◯
(1) Controlled treated, BP < 140/90 97 (13.9) 143 (25.0)* 240 (18.9) 1357 (10.1)◯
(2) Uncontrolled treated, > = 140/90 271 (38.8) 249 (43.5)* 520 (40.9) 2495 (18.6)◯
(3) Known, but not treated, > = 140/90 51 (7.3) 34 (5.9) 85 (6.7) 1178 (8.8)◯
(4) Unknown, > = 140/90 144 (20.6) 59 (10.3)* 203 (16.0) 2904 (21.6)◯
Untreated or insufficiently treated (groups 2, 3, 4) 466 (66.8) 342 (59.8)* 808 (63.6) 6577 (48.9)◯
GNHIES98 101 (72.1) 94 (67.6) 195 (69.9) 1904 (61.4)◯
CARLA 72 (75.8) 42 (53.9)* 114 (65.9) 668 (55.3)◯
DHS 39 (75.0) 24 (68.6) 63 (72.4) 503 (63.3)
KORA 49 (61.3) 37 (56.9) 86 (59.3) 898 (39.3)◯
HNR 107 (52.7) 66 (49.6) 173 (51.5) 1504 (36.8)◯
SHIP 98 (76.6) 80 (65.0)* 178 (70.9) 1110 (55.7)◯
Complete cases dyslipidemia n(cc) = 639 n(cc) = 522 n(cc) = 1161 n(cc) =12451
No dyslipidemia 277 (43.4) 248 (47.5) 525 (45.2) 8004 (64.3)◯
Dyslipidemia 362 (56.7) 274 (52.5) 636 (54.8) 4447 (35.7)◯
(1) Controlled treated , TC/HDL <5 65 (10.2) 78 (14.9) 143 (12.3) 861 (6.9)◯
(2) Uncontrolled treated, > = 5 43 (6.7) 41 (7.9) 84 (7.2) 299 (2.4)◯
(3) Known, but not treated, > = 5 114 (17.8) 85 (16.3) 199 (17.1) 1535 (12.3)◯
(4) Unknown, > = 5 140 (21.9) 70 (13.4)* 210 (18.1) 1752 (14.1)◯
Untreated or insufficiently treated (groups 2, 3, 4) 297 (46.5) 196 (37.6)* 493 (42.5) 3586 (28.8)◯
GNHIES98 73 (54.9) 62 (48.8) 135 (51.9) 1040 (35.3)◯
CARLA 34 (35.8) 18 (23.1) 52 (30.1) 280 (23.3)
(DHS)◖ (15 (31.3)) (7 (22.6)) (22 (27.9) (105 (14.7)
KORA 39 (48.8) 24 (38.1) 63 (44.1) 675 (29.7)◯
HNR 87 (42.9) 41 (31.1)* 128 (38.2) 996 (24.5)◯
SHIP 64 (50.0) 51 (41.5) 115 (45.8) 600 (30.4)◯
BP: blood pressure, TC: total cholesterol, HDL: high density lipoprotein n(cc) = number of complete cases concerning variables used for these statistics,
i.e. physician's diagnosis, medication intake and BP measurement or lipid measurement, respectively.
*Test of the difference between T2D men and T2D women, p <0.05.
◯Test of the difference between all T2D subjects and all non-T2D subjects, p < 0.05.
◖without consideration of physician's diagnosis because this variable was missing in DHS.
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failing to reach the blood pressure target (OR=1.43, 95%
CI 1.26-1.61) (Table 4). Age and male sex were also signifi-
cantly associated with unfavourable blood pressure levels.
Using the nationwide and oldest study, GNHIES98, as refer-
ence, all regional studies except DHS achieved more
favourable results. The interaction term of age and sex was
significant, indicating that in women the odds of hyperten-
sion increased more steeply with increasing age than in men.
Dyslipidemia (n=14735) was also positively associated
with diabetes status (OR=1.80, 95% CI 1.59-2.04) and male
sex (OR=3.01, 95% CI 2.79-3.25). All regional studies
reported a significantly lower number of participants withTC/HDL>= 5 than GNHIES98. Interaction of diabetes and
sex showed that women with diabetes had a much higher
odds of dyslipidemia (OR=2.32, 95% CI 1.91-2.82) than
men with diabetes (OR=1.37, 95% CI 1.16-1-61). More-
over, in women the odds increased with increasing age,
while in men, the odds decreased slightly.
The odds of anti-hypertensive treatment in hypertensive
patients (n=8982) were clearly higher in subjects with T2D
(OR=2.86, 95% CI 2.44-3.35), older and female participants
(Table 5). Compared to GNHIES98, participants of
CARLA, HNR and SHIP used anti-hypertensive medication
more frequently. Men received medication more likely with
increasing age than women.
Figure 2 Frequencies of controlled treated, uncontrolled,
known but untreated and unknown hypertension in
participants with T2D. Hypertension was defined
as BP >= 140/90 mmHg, N= 1270.
Rückert et al. Cardiovascular Diabetology 2012, 11:50 Page 8 of 14
http://www.cardiab.com/content/11/1/50In persons with dyslipidemia (n=5083), lipid-lowering
preparations were also used more often by participants
with T2D (OR=1.38, 95%CI 1.15-1.65), older participants
(OR=1.06, 95% CI 1.05-1.07) and women (OR for men:
0.59, 95%CI 0.52-0.67). CARLA, HNR and SHIP had
higher rates of lipid-lowering medication than GNHIES98.
DHS was not included in this model. The odds of taking
lipid-lowering medications increased significantly with in-
creasing age in participants without T2D, but not in parti-
cipants with T2D.
Some interaction terms involving the ‘individual study’
variable were also statistically significant (Tables 4 and 5).Anti-hypertensive treatment regimens
Anti-hypertensive treatment regimens were assessed in
participants who were aware of their condition (subgroups
1 and 2, N=4612) only, assuming that individuals who
received medications without having a physician’s diagno-
sis of hypertension used these preparations for different
indications (e.g. cardiac insufficiency). Participants withFigure 3 Frequencies of controlled treated, uncontrolled,
known but untreated and unknown dyslipidemia in
participants with T2D. Legend: Dyslipidemia was defined
as TC/HDL Ratio > = 5, N = 1161.T2D received preparations of the ATC groups: C03
(diuretics), C08 (calcium channel blockers) and C09
(preparations acting on the renin-angiotensin system,
including ACE inhibitors and angiotensin II receptor
blockers), more frequently than non-T2D hypertensive
participants (Table 6). Thirty-nine point nine percent of all
760 treated subjects with T2D and 56.2% of 3852 treated
participants without T2D received only one preparation or
preparations of one blood pressure lowering ATC group.
A combination of three or more ATC groups was used by
24.5% of T2D subjects and 12.5% of non-T2D subjects.
Time trends in uncontrolled hypertension
Logistic models including the year of examination of each
study participant adjusted for age, sex, diabetes and study
revealed that there was some improvement of hyperten-
sion treatment during the DIAB-CORE study period, i.e.
from 1997 to 2006. Thus, the odds of having blood pres-
sure values >=140/90 mmHg decreased per year (OR=
0.95 (95% CI 0.90-0.99, p = 0.0248). GNHIES98, as the




Our study confirms that there is a clear gap between mea-
sured blood pressure and blood lipid recommendations
and the actual management in 45 to 74 years old T2D and
non- T2D subjects in the general German population.
More than 60% of participants with T2D did not reach the
conservative blood pressure target of 140/90 mmHg and
about 40% had prevalent dyslipidemia (total cholesterol/
HDL-ratio of >=5). The analysis showed that about 70% of
all T2D participants received anti-hypertensive medication,
but 40% were insufficiently controlled. About 20% of the
participants with T2D used lipid-lowering medication but
7% did not reach a total cholesterol/HDL-ratio of <5 des-
pite medication intake. Approximately 80% of T2D subjects
with currently elevated lipid levels were untreated. T2D
patients had a worse cardiovascular profile compared to
non-T2D subjects.
The choice of anti-hypertensive drugs differed between
participants with and without diabetes, reflecting current
recommendations [37]. Many study participants used only
one ATC group.
The odds of having blood pressure values >=140/
90 mmHg decreased significantly over time. However, since
the single studies differed in the frequency of hypertension
and the individual study periods overlapped only in part,
the effect was difficult to separate from the study effect and
will be studied in more detail using longitudinal data.
We did not especially stress the differences between the
individual studies, since they do not necessarily reflect re-
gional differences in health care. The studies were not
Table 4 Logistic Regression Model: Untreated or insufficiently treated hypertension or dyslipidemia, respectively, in
participants with and without T2D (only participants with missing study measurements were excluded)
Blood pressure>= 140/90 mmHg
n=15045, n (BP>= 140/90 mmHg) = 7551
Total cholesterol/HDL>=5
n=14735, n (TC/HDL>= 5) = 4300
Effect OR 95% CI p-value OR 95% CI p-value
Diabetes yes 1.43 1.26-1.61 <0.0001 1.80 1.59-2.04 <0.0001
Age year 1.05 1.04-1.05 <0.0001 1.01 1.00-1.01 0.0444
Sex male 1.79 1.67-1.91 <0.0001 3.01 2.79-3.25 <0.0001
Study
KORA 0.38 0.34-0.42 <0.0001 0.74 0.66-0.84 <0.0001
CARLA 0.68 0.60-0.78 <0.0001 0.48 0.42-0.56 <0.0001
DHS 0.99 0.85-1.17 0.9446 0.29 0.24-0.36 <0.0001
HNR 0.34 0.31-0.37 <0.0001 0.56 0.51-0.62 <0.0001








Diabetes (yes) Men 1.37 1.16-1.61 0.0002
Women 2.32 1.91-2.82 <.0001
Age (year) Men 1.04 1.03-1.04 <.0001 0.99 0.99-1.00 0.0062
Women 1.05 1.05-1.06 <.0001 1.03 1.02-1.04 <.0001
Stratified analyses were also adjusted for age and study or diabetes and study respectively.
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tory measurements were not standardized from the outset.
The nationwide GNHIES98, SHIP and DHS had more un-
favourable outcomes than the other studies which might
be due to the fact that GNHIES98 and SHIP were the old-
est studies and DHS had the smallest number of partici-
pants and only two blood pressure measurements.
Strengths and limitations
The essential strength of our study is the large population-
based sample drawn from the general German population
aged 45 to 74 years and the fact that both, laboratory mea-
surements and information on medication intake were
available.
Due to the pooling process only similarly collected and
coded data of all six studies could be used and the least
common denominator had to be found. Therefore, the def-
inition of diabetes was based on self-report of physician’s
diagnosis and treatment with anti-diabetic agents rather
than on clinical diagnosis and medical records. Blood pres-
sure was calculated using the mean of the second and third
measurements in all studies except for DHS, where only
two measurements were performed and used to calculatethe mean. This might distort the frequency in DHS and
contribute to the high proportion of participants with
64.2% having a blood pressure >= 140/90 mmHg com-
pared to 49.3% in the other studies.
Moreover, measurements of blood pressure and lipids
based on a single testing opportunity present evidence for
the respective condition, but are not equal to a clinical diag-
nosis with repeated measurements. We cannot exclude
cases of ‘white coat hypertension’, i.e. elevated blood pres-
sure owing to the excitement of the unfamiliar situation.
Finally, all study participants were asked to bring
packages of their medications to the study centres. How-
ever, due to non-compliance and forgetfulness it is possible
that fewer packages were documented than had actually
been prescribed. We might thus have underestimated
medication intake, consequently overestimated the number
of participants without treatment and probably underesti-
mated the number of participants with insufficient
treatment.
Generalization
The results of our population-based study fortify the findings
of patient-based German and international studies. Recently,
Table 5 Logistic Regression Model: Medical treatment in participants with hypertension (including unknown
hypertension) or dyslipidemia (including unknown dyslipidemia), respectively
Anti-hypertensive medication
n= 8982, n (med) = 4958
Lipid-lowering medication
n= 5083, n (med) = 1443
Effect OR 95% CI p-value OR 95% CI p-value
Diabetes yes 2.86 2.44-3.35 <0.0001 1.38 1.15-1.65 0.0006
Age year 1.07 1.06-1.07 <0.0001 1.06 1.05-1.07 <0.0001
Sex male 0.64 0.58-0.70 <0.0001 0.59 0.52-0.67 <0.0001
Study
KORA 1.33 1.15-1.54 <0.0001 1.25 1.01-1.53 0.0383
CARLA 1.95 1.66-2.30 <0.0001 1.94 1.53-2.50 <0.0001
DHS 0.93 0.77-1.12 0.4219 *- - -
HNR 1.96 1.73-2.22 <0.0001 1.96 1.64-2.33 <0.0001
SHIP 1.68 1.47-1.93 <0.0001 1.27 1.03-1.56 0.0232
GNHIES98 Ref. Ref.
Interactions





Age (year) T2D 1.02 1.00-1.05 0.0593
Non-T2D 1.06 1.05-1.07 <.0001
Age (year) Men 1.08 1.07-1.09 <.0001
Women 1.05 1.04-1.06 <.0001
*no information on physician’s diagnosis in DHS.
Stratified analyses were also adjusted for sex and study or diabetes and study respectively.
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patients from the German T2DSD-registry DUTY had un-
controlled systolic blood pressure >= 140 mmHg and about
50% had uncontrolled LDL cholesterol values>= 3.4 mmol/
l. These proportions differed slightly with atherosclerotic dis-
ease location. The German ESTHER Study published in
2008 found that 78% of diabetes patients had hypertension
diagnosed by a physician and only 12.8% of those who
received anti-hypertensive pharmacotherapy achieved blood
pressure levels below 130/85 mmHg. Physician diagnosed
dyslipidemia was reported in 50% of all patients [17].
A nationwide French survey conducted in 2001 and in-
volving 410 diabetologists found that the target blood pres-
sure of < 140/80 mmHg was attained by 29% of patients
and 58% had LDL values of < than 1.3 g/l. Control of blood
pressure and LDL was not considered to be optimal [38].
Similarly, the authors of a Canadian study [13] concluded
that T2D patients with cardiovascular co-morbidities are
insufficiently treated with medication, perhaps because of
the “glucocentric view” of diabetes. They focused on anti-
platelet agents, statins and ACE inhibitors. Godley et al.
[14] used insurance claims data of 977 hypertensive T2Dpatients in the US. Only 19.7% reached the stricter blood
pressure goal of < 130/85 mmHg and 52% had dyslipidemia.
A recently published US investigation by DeGuzman et al.
[39] including 926 high risk patients with diabetes and con-
comitant atherosclerotic CVD found that although the vast
majority of patients were prescribed recommended drug
therapy and mean cholesterol and BP values were satisfac-
tory, the percentage of patients actually treated to goals of
current guidelines was moderate. About 40% had LDL
values <= 70 mg/dl and about 60% reached a systolic BP of
<= 130 mmHg.
Finally, data from 9,167 participants of the US NHANES
(National Health and Nutrition Examination Survey) survey
[40] showed that alongside an increasing prevalence of dia-
betes from 1999 to 2008 the frequency of self reported use
of lipid lowering medication increased significantly. Accord-
ingly, the proportion of participants reaching the LDL chol-
esterol goal of < 100 mg/dl also increased significantly from
about 30% to about 50%. Although the use of antihyperten-
sive preparations increased significantly from about 35% to
about 60%, there was no change in the proportion of parti-
cipants achieving the BP goal of <= 130/80 mmHg (about
Table 6 Medication groups used for treating hypertensive T2D and non-T2D participants respectively





















C02 Anti-hypertensives 9.47 2.11 8.00 2.78
C03 Diuretics 29.47 2.50 17.29* 2.52 not ideal as first line treatment
since they can worsen glucose
and lipid levels
C04 Peripheral vasodilators 4.21 0.13 2.65* 0.31
C07 Beta blocking agents 44.74 8.82 52.23* 23.81* best used as second- or third-line
treatments in T2D, more efficacious
in younger patients (55–60 years),
not for asthma patients, because of
bronchoconstrictive effects, promote




33.68 5.79 27.13* 7.84* not recommended as first-line
and single treatment
C09 Agents acting on the
renin-angiotensin
system
68.95 20.53 51.43* 18.98 recommended as first-line
treatment, reduce the risk for
renal end points
* p for the difference between participants with T2D and participants without T2D <0.05.
Anti-hypertensive medication in participants who were classified as non-hypertensive or unknown was not considered in this analysis, assuming that they used
these agents for different indications.
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attained both the LDL and BP targets simultaneously.
The scientific community engaged in health care man-
agement strongly postulates an aggressive treatment of dys-
lipidemia and hypertension and advocates the widespread
use of drugs to effectively improve mortality and morbidity
rates in patients at risk [41]. A large number of blood pres-
sure lowering preparations is available today. The choice of
agents depends on individual intolerances and the thera-
peutic effect that varies among subjects. However, though
general recommendations for T2D patients exist, there is
large diversity in diabetes care programs [42] and uncer-
tainty as to which medication classes are most suitable for
patients with diabetes. Usually more than one preparation
is needed to achieve the target value [1].
In general, ACE inhibitors should be used first, accompan-
ied by diuretics depending on the presence of co-morbidities.
Yet diuretics alone are suspected to negatively influence
blood glucose [43]. Beta blockers, AT1 blockers and calcium
antagonists are recommended as well [2,44]. Beta blockers
are believed to mask hypoglycaemia in patients with T2D,
though evidence suggests that that is not the case [45].
Further reductions of blood pressure target values seem
not to be advisable though [32]. Recently, the ACCORD
study has given evidence that the reduction of systolic
blood pressure to 120 mmHg did not reduce the primary
endpoint (a composite of stroke, myocardial infarction and
cardiovascular death) compared with the control group, inwhich a systolic blood pressure of 140 mmHg was targeted
[46]. Due to severe adverse reactions caused by anti-
hypertensive medication the overall mortality rate was even
higher. Moreover, some renal markers were alarmingly
impaired. The number of stroke cases, though, could be
lowered by 41%. The results of the ACCORD lipid substudy
were similarly disappointing [47]: Tight control of triglycer-
ides and HDL cholesterol values was achieved with a com-
bination of fenofibrates and statins. The endpoints were
not significantly reduced.
Statins are usually prescribed to treat dyslipidemia. They
are regarded as safe, provide significant cardiovascular ben-
efits in different populations including the elderly and
patients with diabetes, and may halt or slow atherosclerotic
disease progression [48]. Recently, concerns have been
raised that statins may increase the risk of developing dia-
betes in postmenopausal women [49] and with intensive-
dose treatment compared to moderate-dose treatment
[50]. However, the authors concluded that the mechanisms
remain unclear and the putative risk needs to be balanced
to well-known benefits.
Over and above, insufficient blood pressure and lipid con-
trol are not exclusively due to insufficient prescription of
medication but to various factors related to the patient and
the physician. Important aspects are insufficient awareness
and motivation of the patient, reluctance to initiate lifestyle
changes, poor compliance (e.g. because of forgetfulness, tol-
erability problems due to adverse side effects, polypharmacy
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therapy, when it is indicated such as use of combination
therapy if monotherapy proves to be inadequate [51,52].
Thus, apart from medication and its design, to improve
secondary prevention of cardiovascular disease in primary
physician health care and especially in T2D patients, the
following intervention programmes should be emphasized
[14]: education sessions for practitioners, medical manage-
ment guidelines, physician profiling of prescribing patterns,
and blood pressure monitoring kits for patients and patient
education. A prominent example are T2D disease manage-
ment programs (DMPs) implemented by the German social
health insurance companies in 2003 which have already
shown the improvement of healthcare processes and blood
pressure control [53].
According to a small study by Asimakopoulou et al. [54],
T2D patients are aware of their increased cardiovascular
risk and even tend to overestimate it. However, in contrast
to realistic informed concern that may motivate to choose a
healthier lifestyle, immoderate anxiety and fear may lead to
ignorance and repression including poor compliance with
medical treatment.
Therefore, individual counselling and risk communication
between a health professional and the patient is essential.
Conclusions
In conclusion, our analysis based on a large dataset from six
population-based studies provides evidence that, among
comprehensive lifestyle interventions, health care in T2D
patients in Germany could be remarkably improved by fo-
cusing on cardiovascular risk factors, especially blood pres-
sure and lipid concentration. Though numerous guidelines
on the topic have been published, the transfer of theoretical
knowledge to practical application appears to be very diffi-
cult. Physicians may stick to the “glucocentric view” of
diabetes therapy and fail to recognise the severity of cardio-
vascular risk factors and co-morbidities. This approach may
limit microvascular disease, but lacks the important focus
on macrovascular complications.
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